A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT07107373
- Status
- Active Not Recruiting
Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Mavacamten — DRUGAccording to the product label
Study Details
The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US
Key Dates
- Start date
- Dec 22, 2023
- Status verified
- Jul 2025
- Primary completion
- Jul 26, 2024
- Completion
- Dec 31, 2025
Study Design
- Enrollment
- 150 participants (estimated)
Arms
- Arm: Participants receiving treatment mavacamten
Primary Outcome Measure
New York Heart Association (NYHA) functional class [ Time Frame: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, and in increments of 12 weeks thereafter from index ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Francisco (UCSF) | San Francisco | California | 94118 | - |